• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Market characteristics
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 - 2025
• Five Forces Analysis
o Five Forces Summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o Long-acting insulins - Market size and forecast 2020-2025
o Rapid-acting insulins - Market size and forecast 2020-2025
o Pre-mixed insulins - Market size and forecast 2020-2025
o Non-insulin drugs - Market size and forecast 2020-2025
o Market opportunity by Product
• Customer Landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America - Market size and forecast 2020-2025
o Europe - Market size and forecast 2020-2025
o Asia - Market size and forecast 2020-2025
o ROW - Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Actiza Pharmaceutical Pvt. Ltd.
o Astellas Pharma Inc.
o AstraZeneca Plc
o Biocon Ltd.
o Bristol-Myers Squibb Co.
o Eli Lilly and Co.
o MannKind Corp.
o Novo Nordisk AS
o Sanofi SA
o Viatris Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global - Market size and forecast 2020 - 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 - 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition - Five forces 2020
• 21: Long-acting insulins - Market size and forecast 2020-2025 ($ million)
• 22: Long-acting insulins - Year-over-year growth 2020-2025 (%)
• 23: Rapid-acting insulins - Market size and forecast 2020-2025 ($ million)
• 24: Rapid-acting insulins - Year-over-year growth 2020-2025 (%)
• 25: Pre-mixed insulins - Market size and forecast 2020-2025 ($ million)
• 26: Pre-mixed insulins - Year-over-year growth 2020-2025 (%)
• 27: Non-insulin drugs - Market size and forecast 2020-2025 ($ million)
• 28: Non-insulin drugs - Year-over-year growth 2020-2025 (%)
• 29: Customer landscape
• 30: Impact of drivers and challenges
• 31: Vendor landscape
• 32: Landscape disruption
• 33: Industry risks
• 34: Vendors covered
• 35: Market positioning of vendors
• 36: Actiza Pharmaceutical Pvt. Ltd. - Overview
• 37: Actiza Pharmaceutical Pvt. Ltd. - Product and service
• 38: Actiza Pharmaceutical Pvt. Ltd. - Key offerings
• 39: Actiza Pharmaceutical Pvt. Ltd. - Key customers
• 40: Actiza Pharmaceutical Pvt. Ltd. - Segment focus
• 41: Astellas Pharma Inc. - Overview
• 42: Astellas Pharma Inc. - Product and service
• 43: Astellas Pharma Inc. - Key offerings
• 44: Astellas Pharma Inc. - Key customers
• 45: Astellas Pharma Inc. - Segment focus
• 46: AstraZeneca Plc - Overview
• 47: AstraZeneca Plc - Product and service
• 48: AstraZeneca Plc - Key offerings
• 49: AstraZeneca Plc - Key customers
• 50: AstraZeneca Plc - Segment focus
• 51: Biocon Ltd. - Overview
• 52: Biocon Ltd. - Business segments
• 53: Biocon Ltd. - Key offerings
• 54: Biocon Ltd. - Key customers
• 55: Biocon Ltd. - Segment focus
• 56: Bristol-Myers Squibb Co. - Overview
• 57: Bristol-Myers Squibb Co. - Product and service
• 58: Bristol-Myers Squibb Co. - Key offerings
• 59: Bristol-Myers Squibb Co. - Key customers
• 60: Bristol-Myers Squibb Co. - Segment focus
• 61: Eli Lilly and Co. - Overview
• 62: Eli Lilly and Co. - Business segments
• 63: Eli Lilly and Co. - Key offerings
• 64: Eli Lilly and Co. - Key customers
• 65: Eli Lilly and Co. - Segment focus
• 66: MannKind Corp. - Overview
• 67: MannKind Corp. - Business segments
• 68: MannKind Corp. - Key offerings
• 69: MannKind Corp. - Key customers
• 70: MannKind Corp. - Segment focus
• 71: Novo Nordisk AS - Overview
• 72: Novo Nordisk AS - Business segments
• 73: Novo Nordisk AS - Key offerings
• 74: Novo Nordisk AS - Key customers
• 75: Novo Nordisk AS - Segment focus
• 76: Sanofi SA - Overview
• 77: Sanofi SA - Business segments
• 78: Sanofi SA - Key offerings
• 79: Sanofi SA - Key customers
• 80: Sanofi SA - Segment focus
• 81: Viatris Inc. - Overview
• 82: Viatris Inc. - Business segments
• 83: Viatris Inc. - Key offerings
• 84: Viatris Inc. - Key customers
• 85: Viatris Inc. - Segment focus
• 86: Currency conversion rates for US$
• 87: Research Methodology
• 88: Validation techniques employed for market sizing
• 89: Information sources
• 90: List of abbreviations

Companies Mentioned
. Astellas Pharma Inc.
. AstraZeneca Plc
. Biocon Ltd.
. Bristol-Myers Squibb Co.
. Eli Lilly and Co.
. MannKind Corp.
. Novo Nordisk AS
. Actiza Pharmaceutical Pvt. Ltd.
. Sanofi SA
. Viatris Inc.